June 4, 2013
John Neil Primrose, Southampton General Hospital The PIII study “New EPOC,” which investigated the efficacy of cetuximab (brand name: Erbitux) as an add-on therapy to chemotherapy in KRAS wild-type patients with operable colorectal cancer, failed to demonstrate the extension of...read more